European Commission logo
English English
CORDIS - EU research results

Multidisciplinary European network for research, prevention and control of the COVID-19 Pandemic

Project description

A European front against COVID-19

To understand the mode of infection and pathogenicity of any emerging virus, it is necessary to rapidly integrate epidemiological, clinical and virological information. In this context, the EU-funded I-MOVE-COVID-19 project is developing a flexible surveillance platform for pooling European results, based on common protocols on the COVID-19 pandemic. The project expands on the existing Europe-wide influenza monitoring vaccine effectiveness (I-MOVE) network to include studies on COVID-19. Through the mobilisation of a large European multidisciplinary network of relevant expertise, it hopes to contribute to the clinical management of patients, improve public health preparedness and response to COVID-19 and evaluate COVID-19 vaccine effectiveness once the vaccine will be available.


I-MOVE-COVID-19 aims to obtain epidemiological, clinical and virological information about COVID-19 and patients infected with SARS-CoV-2, through provision of a flexible surveillance platform (adaptable to the epidemiological situation), research studies, hypothesis-testing and evaluation of public health interventions (e.g. vaccination, antivirals) in order to contribute to the knowledge base, guide patient management, and inform the public health response. This will be achieved through adaptation and expansion of the existing, long-running, Europe-wide influenza surveillance network (I-MOVE) to include COVID-19. The network includes primary care networks, hospitals, national laboratory reference centres in eleven countries.

I-MOVE-COVID-19 priority activities and research projects will be selected based on ECDC/WHO input and the proposal’s detailed list. These will be conducted by mobilising an existing large European multidisciplinary network, combining the expertise and resources of groups working in surveillance (epidemiological, clinical, virological), respiratory disease research, and evaluation of vaccines/treatments. Through protocol sharing and pooling European results, questions will be answered which could not be efficiently answered by countries acting alone. I-MOVE-COVID-19 will share study results rapidly and widely with national and international partners and with the wider scientific community and contribute to clinical management of patients and public health preparedness and response to COVID-19.


Net EU contribution
€ 374 043,50
75011 Paris

See on map


The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Ile-de-France Ile-de-France Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Total cost
€ 509 062,50

Participants (32)